Teachers Retirement System of The State of Kentucky Takes $11.90 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Teachers Retirement System of The State of Kentucky acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 59,457 shares of the biopharmaceutical company’s stock, valued at approximately $11,900,000.

Several other institutional investors have also recently added to or reduced their stakes in ALNY. Nuveen Asset Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 5,486.1% during the third quarter. Nuveen Asset Management LLC now owns 16,593,268 shares of the biopharmaceutical company’s stock worth $3,321,309,000 after buying an additional 16,296,223 shares in the last quarter. Vanguard Group Inc. grew its stake in Alnylam Pharmaceuticals by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock worth $1,768,291,000 after acquiring an additional 126,373 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Alnylam Pharmaceuticals by 3.0% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,997,082 shares of the biopharmaceutical company’s stock valued at $1,020,524,000 after acquiring an additional 202,916 shares during the last quarter. State Street Corp lifted its stake in shares of Alnylam Pharmaceuticals by 2.7% during the 2nd quarter. State Street Corp now owns 2,988,859 shares of the biopharmaceutical company’s stock worth $435,925,000 after purchasing an additional 79,369 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of Alnylam Pharmaceuticals by 8.8% during the first quarter. Invesco Ltd. now owns 968,755 shares of the biopharmaceutical company’s stock worth $158,187,000 after purchasing an additional 78,665 shares during the last quarter.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 18,072 shares of the firm’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $200.00, for a total transaction of $3,614,400.00. Following the completion of the sale, the chief marketing officer now owns 4,345 shares in the company, valued at approximately $869,000. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Alnylam Pharmaceuticals news, EVP Indrani Lall Franchini sold 1,675 shares of the company’s stock in a transaction that occurred on Thursday, February 2nd. The stock was sold at an average price of $226.01, for a total transaction of $378,566.75. Following the sale, the executive vice president now owns 3,500 shares in the company, valued at $791,035. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 18,072 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $200.00, for a total value of $3,614,400.00. Following the completion of the transaction, the chief marketing officer now owns 4,345 shares of the company’s stock, valued at approximately $869,000. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on ALNY. EF Hutton Acquisition Co. I initiated coverage on Alnylam Pharmaceuticals in a research report on Tuesday, February 21st. They set a “buy” rating and a $304.00 target price on the stock. Oppenheimer decreased their target price on shares of Alnylam Pharmaceuticals from $256.00 to $249.00 and set an “outperform” rating on the stock in a research report on Friday, February 24th. HC Wainwright reaffirmed a “buy” rating and set a $415.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, March 3rd. JPMorgan Chase & Co. cut their price target on shares of Alnylam Pharmaceuticals from $200.00 to $196.00 and set a “neutral” rating on the stock in a research note on Friday, March 3rd. Finally, Piper Sandler boosted their price objective on shares of Alnylam Pharmaceuticals from $226.00 to $253.00 and gave the company an “overweight” rating in a research note on Friday, December 16th. Seven research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $244.26.

Alnylam Pharmaceuticals Trading Up 2.1 %

ALNY opened at $189.66 on Friday. The firm has a market capitalization of $23.54 billion, a P/E ratio of -20.42 and a beta of 0.49. The firm’s 50 day moving average is $214.61 and its 200-day moving average is $213.51. The company has a quick ratio of 3.34, a current ratio of 3.51 and a debt-to-equity ratio of 3.85. Alnylam Pharmaceuticals, Inc. has a 52-week low of $117.58 and a 52-week high of $242.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last released its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.13) by $0.45. The firm had revenue of $335.04 million for the quarter, compared to the consensus estimate of $312.45 million. Alnylam Pharmaceuticals had a negative net margin of 109.04% and a negative return on equity of 1,287.80%. The firm’s quarterly revenue was up 29.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.16) EPS. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -6.93 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.